10/12/2002
ReGen Therapeutics plc announces that at the Extraordinary General Meeting of the company held earlier today, all of the resolutions were unanimously passed.
ReGen also announces that following a presentation today to analysts and investors on corporate strategy, a scientific update and plans for future development of ColostrininTM, the company’s potential treatment for Alzheimer’s Disease, the company has posted copies of the presentation on its website.
Further information:
Andrew Marshall
Marshall Robinson Roe
Tel: 020 7489 2033